Exploration of the effects of fospropofol disodium in anesthesia induction for elderly hip surgery

Randomized controlled trial of fospropofol disodium versus etomidate for anesthetic induction in elderly patients undergoing hip surgery: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12170320

Enrollment

120

Registered

2025-06-24

Start date

2025-07-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly hip surgery patients Surgery

Interventions

Patients were randomly allocated into two groups (1:1 ratio) using a computer-generated randomisation list created by an independent biostatistician before patient enrolment. Block randomisation was n

Eligibility

Sex/Gender

All

Age

65 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1.Elderly patients (65-74 years) 2.BMI 18-27 kg/m² 3.ASA physical status I-III 4.Scheduled for hip surgery under general anesthesia requiring endotracheal intubation

Exclusion criteria

Exclusion criteria: 1. Refusal of general anesthesia 2. Allergy to general anesthetics 3. Preoperative cognitive impairment or significant hepatic/renal dysfunction 4. Baseline blood pressure =180/110 mmHg or =90/60 mmHg 5. Symptomatic cardiovascular, cerebrovascular, or respiratory diseases 6. Scheduled for bilateral joint surgery 7. Revision arthroplasty 8. Polytrauma 9. History of systemic or regional anesthesia within 3 months

Design outcomes

Primary

Measure	Time frame
Time to loss of consciousness, measured by recording the interval from drug injection until both disappearance of the eyelash reflex and failure to respond to verbal command on two consecutive attempts	—

Secondary

Measure	Time frame
1. Hemodynamic parameters including heart rate, systolic, diastolic, and mean arterial pressure are measured using noninvasive monitoring at before induction of anesthesia, loss of consciousness ,immediately after tracheal intubation ,surgical incision,20 minutes after surgical incision 2. Side effects including postoperative nausea and vomiting are documented based on clinical observation and medication use within the first 24 hours 3. Recovery Time is recorded based on the time to extubation time after surgery 4. postoperative delirium is measured using a Confusion Assessment Method scale at 48 hours postoperatively 5. Success rate of anesthesia induction is measured using counting successful inductions as a proportion of the total number of participants in each group 6. Incidence of injection pain and myoclonus within 30 seconds of initial dose administration are documented based on clinical observation 7. Total dosage of sufentanil, remifentanil, propofol, and vasoactive drugs used is measured using data obtained from the intravenous device	—

Measure

Time frame

1. Hemodynamic parameters including heart rate, systolic, diastolic, and mean arterial pressure are measured using noninvasive monitoring at before induction of anesthesia, loss of consciousness ,immediately after tracheal intubation ,surgical incision,20 minutes after surgical incision 2. Side effects including postoperative nausea and vomiting are documented based on clinical observation and medication use within the first 24 hours 3. Recovery Time is recorded based on the time to extubation time after surgery 4. postoperative delirium is measured using a Confusion Assessment Method scale at 48 hours postoperatively 5. Success rate of anesthesia induction is measured using counting successful inductions as a proportion of the total number of participants in each group 6. Incidence of injection pain and myoclonus within 30 seconds of initial dose administration are documented based on clinical observation 7. Total dosage of sufentanil, remifentanil, propofol, and vasoactive drugs used is measured using data obtained from the intravenous device

—

Countries

China

Contacts

Public ContactLan Qiu

qiulanmz@163.com+86 519-68870312

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 10, 2026